The European Association of Euro-Pharmaceutical Companies (EAEPC), European Federation of Pharmaceutical Industries and Associations (EFPIA), Groupement International de la Repartition Pharmaceutique (GIRP) and Pharmaceutical Group of the European Union (PGEU) have welcome the European Directorate for the Quality of Medicines & Healthcare (EDQM)’s involvement in the fight against counterfeit medicines entering the European supply chain.
EDQM presented its “eTact” coding system at a meeting in Strasbourg, France, today and the organisations agreed that it is essential to develop a practical and cost-effective solution to implement the requirements of the Falsified Medicines Directive in Europe.
“Our European Stakeholder Model (ESM) is easily adaptable to any existing national systems,” said PGEU Secretary General John Chave.
“It offers a product verification solution which can be implemented without unnecessary cost or disruption,”
EAEPC, EFPIA, GIRP and PGEU are jointly working on the ESM to prevent falsified medicines from entering the European supply chain and improve patient safety.
“This joint approach clearly offers distinct advantages in terms of efficiency and expertise to run the system”, said Monika Derecque-Pois, Director General of GIRP.
Heinz Kobelt, EAEPC European Affairs Director, added: “We believe serialisation is an effective tool to undermine the business model of counterfeiters.
“This joint stakeholders’ system represents a big step forward in ensuring the safety of the medicinal supply chain for European patients and operators alike.”
Richard Bergström, EFPIA Director General, concluded: “Our vision is to develop a harmonised system that provides a high level of security for patients while being cost effective and integrating into existing structures in the distribution chain.”